Printer Friendly

SANDOZ GROUP REPORTS SALES FOR NINE MONTHS YEAR TO DATE

 SANDOZ GROUP REPORTS SALES FOR NINE MONTHS YEAR TO DATE
 BASEL, Switzerland, Oct. 22 /PRNewswire/ -- The Sandoz Group achieved Sfr. 11.1 billion in consolidated sales in the first nine months of 1992. This is an increase of 9 percent over the same period last year. In local currencies, excluding the impact of high-inflation countries, sales grew by 7 percent.
 Sales developed as follows:
 SANDOZ GROUP
 Variance
 Nine Months In Sfr In Local
 1992 1991 Pctg. Currencies(A)
 Sfr. Millions Sfr. Millions Pctg.
 Chemicals 1,872 1,784 5 5
 Pharmaceuticals 5,171 4,693(B) 10 9
 Agro 970 949 2 -1
 Seeds 876 801 9 5
 Nutrition 1,357 1,128 20 16
 Construction &
 Environment 817 784 4 3
 Total 11,063 10,139 9 7
 (A) excluding high-inflation countries
 (B) figures for the previous year have been adjusted to reflect changes in billing practices
 Strong recessionary tendencies, combined with turbulence in the European Monetary System and the weakness of the U.S. dollar, have had an overall dampening effect on the world economy. Against this background, our sales growth of over Sfr. 900 million or 9 percent is satisfactory. All divisions improved their performances over the same period in 1991.
 The growth of Pharma -- the largest division -- continued on the strength of its innovative specialities. In addition to our market leaders Sandimmun(R) and Leponex(R)/Clozaril(R), particularly gratifying growth was achieved by the new products Lamisil(R), Sandostatin(R) and Lomir(R)/DynaCirc(R). In the face of difficult market conditions, the growth rates of Chemicals, Agro and Construction & Environment were all the more positive. Likewise, the performance of Seeds was gratifying. Nutrition continues its dynamic expansion.
 In light of the performance in the nine months to date, we expect a further increase in annual profits thanks to our innovative products and continuing strict cost management.
 -0- 10/22/92
 /CONTACT: James R. Simpson of Sandoz Corp., 212-830-2444/ CO: Sandoz Group ST: IN: MTC SU:


SM-EE -- NY030 -- 3390 10/22/92 09:56 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 22, 1992
Words:339
Previous Article:INVACARE ANNOUNCES HIGHEST QUARTERLY SALES AND EARNINGS IN COMPANY'S HISTORY
Next Article:SEARS REPORTS QUARTERLY EARNINGS
Topics:


Related Articles
IMCERA'S MALLINCKRODT MEDICAL UNIT AND SANDOZ PHARMA LTD. SIGN AGREEMENT TO SHARE MOLECULAR RESEARCH
SANDOZ HIGHLIGHTS ITS 1993 RESULTS AND ANNOUNCES 1994 FIRST QUARTER SALES
SANDOZ ANNOUNCES SALES TO SEPTEMBER 30, 1994: 9% GROWTH IN LOCAL CURRENCIES
SANDOZ ANNOUNCES FIRST HALF SALES UP 17% IN LOCAL CURRENCIES, 6% IN SWISS FRANCS
SANDOZ ANNOUNCES 16% GROWTH IN LOCAL CURRENCIES FOR SALES TO SEPTEMBER 30
Ciba Group in the First 9 Months of 1996 Generic Competition To Voltaren and Lopressor Slowed Growth in Pharma
Sandoz Inc. Launches AB-Rated Levothyroxine; - Generic Treatment for Hypothyroidism Provides Lower Cost Alternative for Patients -.
Sandoz Inc. Launches AB-Rated Levothyroxine.
Sandoz Receives FDA Approval for Generic Toprol XL(R) 50 mg Tablet.
Sandoz Launches Generic Version Of Toprol XL(R) 50 Mg ER Tablet.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters